Signadori Bio appoints Dr Selwyn Ho as CEO to drive company growth
Signadori Bio, a preclinical-stage biopharmaceutical company developing a next generation, off-the shelf, in vivo engineered, monocyte immunotherapy platform to treat solid tumours, recently announced the appointment of Dr. Selwyn Ho as Chief Executive Officer. Dr. Ho is an experienced biopharma and biotech executive, with nearly 30 years of experience across commercialisation, drug development and multiple […]
Vertex enters into a definitive agreement to acquire Alpine Immune Sciences
Vertex Pharmaceuticals Incorporated and Alpine Immune Sciences, Inc., a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, yesterday announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9 billion in cash. The transaction was unanimously approved by both the Vertex and […]
